Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | HORIZON: melflufen & dexamethasone in myeloma

Meral Beksac • 24 Jun 2020
EHA 2020
Multiple Myeloma Antibodies Dexamethasone Melflufen
FORTE HORIZON

Meral Beksac, MD, of Ankara University, Ankara, Turkey, discusses the results of the HORIZON study (NCT02963493), which investigated melflufen in combination with dexamethasone in the treatment of multiple myeloma in adult patients with disease refractory to pomalidomide and/or an anti-CD38 monoclonal antibody. Furthermore, Dr Beksac discusses the significance of PET as a measure of disease response in this indication as evaluated in the FORTE trial (NCT02203643) presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meral Beksac

3:36
Ex vivo expanded NK cells for hematological cancer immunotherapy
Meral Beksac • 11 Dec 2023
3:52
EMN19: Dara-VCd in patients with multiple myeloma and extramedullary disease
Meral Beksac • 12 Dec 2023
2:16
The value of the early relapse EBMT score in multiple myeloma
Meral Beksac • 28 Sep 2023
1:30
Exploring the role of upfront autoSCT in multiple myeloma
Meral Beksac • 28 Sep 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals